The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, talk ...

Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.

In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, discuss ...

This year’s conference highlighted a number of critical areas in clinical R&D including financial management, representation, ...

In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, address ...

Genomics has long been a primary focus in precision medicine, but other areas of research are increasingly being used to help ...

At the current rate of progress, it will take until 2158 to reach full gender parity based on a global measure of opportunity ...

In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...

A tool-based approach can significantly aid in the harmonization of regulatory requirements, mitigate inadvertent risks, and ...